Inhibikase Secures $50 Million Financing To Advance PAH Program

Inhibikase Therapeutics (IKT) shares rose 5% after it sold 25 million shares via an at-the-market facility, raising $50 million in gross proceeds. The equity issuance modestly dilutes existing shareholders, though the cash raise may support ongoing operations and pipeline funding.

Analysis

Inhibikase Therapeutics (IKT) shares rose 5% after it sold 25 million shares via an at-the-market facility, raising $50 million in gross proceeds. The equity issuance modestly dilutes existing shareholders, though the cash raise may support ongoing operations and pipeline funding.